Abnormalities of lipid metabolism and methods of their correction in patients with glomerulonephritis.
The results of integrated estimations of a complex of lipid indices are presented. Their abnormalities are considered to be atherosclerosis risk factors in the evolution of glomerulonephritis and its different variants, types and stages. The quantitative and qualitative peculiarities of the indicated abnormalities are revealed, in particular, their major expressiveness in chronic form, nephrotic variant and in the stage of renal failure. Two aspects of correction of actual abnormalities are singled out: 1. indirect, i.e. treatment of the renal pathologic process with preparation of pathogenetic therapy (glucocorticoids, indomethacin), and 2. direct, i.e. with medications exerting a corrective influence on lipid metabolism (clofibrate, nicotinic acid, curantil). The selection of corrective methods is determined by the stage of disease and by the character of the changes in lipid metabolism.
D000293:Adolescent; D000328:Adult; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002994:Clofibrate / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use
D008055:Lipids; D009525:Niacin; D004176:Dipyridamole; D002994:Clofibrate